Therapeutic uses of peptide nucleic acids (PNA) in oncology

被引:1
作者
Zaffaroni, N [1 ]
Villa, R [1 ]
Folini, M [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy
来源
LETTERS IN PEPTIDE SCIENCE | 2003年 / 10卷 / 3-4期
关键词
bcl-2; cancer; cell-penetrating peptide; c-myc; hammerhead ribozyme; PNA; telomerase;
D O I
10.1007/BF02484564
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peptide nucleic acids (PNAs) are DNA mimics in which the sugar-phosphate backbone has been replaced by an uncharged backbone based on amino acids. Due to their ability to bind to complementary polynucleotides. PNAs have been successfully used to inhibit transcription and/or translation of genes able to confer a survival advantage to cancer cells, such as c-myc and bcl-2. PNAs targeted to the RNA template region of telomerase have also been used to inhibit the catalytic activity of this enzyme, which is responsible for the immortalized phenotype of a large majority of tumor cells. Because it is thought that naked PNAs are not taken up spontaneously by most cells. a number of delivery strategies have been developed including the use of so-called 'cell-penetrating peptides'. Chimeric molecules made by coupling PNAs with such peptides have been shown to accumulate inside tumor cells to an extent sufficient to guarantee the biological effect of PNAs. Overall. these results indicate that PNAs may be useful tools for target-directed anticancer therapeutic interventions.
引用
收藏
页码:287 / 296
页数:10
相关论文
共 51 条
[11]   The hammerhead ribozyme [J].
Eckstein, F .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (03) :601-604
[12]   PNA HYBRIDIZES TO COMPLEMENTARY OLIGONUCLEOTIDES OBEYING THE WATSON-CRICK HYDROGEN-BONDING RULES [J].
EGHOLM, M ;
BUCHARDT, O ;
CHRISTENSEN, L ;
BEHRENS, C ;
FREIER, SM ;
DRIVER, DA ;
BERG, RH ;
KIM, SK ;
NORDEN, B ;
NIELSEN, PE .
NATURE, 1993, 365 (6446) :566-568
[13]   Cell growth: Downstream of Myc - to grow or to cycle? [J].
Elend, M ;
Eilers, M .
CURRENT BIOLOGY, 1999, 9 (24) :R936-R938
[14]   THE RNA COMPONENT OF HUMAN TELOMERASE [J].
FENG, JL ;
FUNK, WD ;
WANG, SS ;
WEINRICH, SL ;
AVILION, AA ;
CHIU, CP ;
ADAMS, RR ;
CHANG, E ;
ALLSOPP, RC ;
YU, JH ;
LE, SY ;
WEST, MD ;
HARLEY, CB ;
ANDREWS, WH ;
GREIDER, CW ;
VILLEPONTEAU, B .
SCIENCE, 1995, 269 (5228) :1236-1241
[15]   Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells [J].
Folini, M ;
Colella, G ;
Villa, R ;
Lualdi, S ;
Daidone, MG ;
Zaffaroni, N .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (02) :259-267
[16]   The MYC dualism in growth and death [J].
Fuhrmann, G ;
Rosenberger, G ;
Grusch, M ;
Klein, N ;
Hofmann, J ;
Krupitza, G .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 1999, 437 (03) :205-217
[17]   Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides [J].
Glukhov, AI ;
Zimnik, OV ;
Gordeev, SA ;
Severin, SE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (02) :368-371
[18]   Protein kinesis - Nucleocytoplasmic transport [J].
Gorlich, D ;
Mattaj, IW .
SCIENCE, 1996, 271 (5255) :1513-1518
[19]   Inhibition of telomerase limits the growth of human cancer cells [J].
Hahn, WC ;
Stewart, SA ;
Brooks, MW ;
York, SG ;
Eaton, E ;
Kurachi, A ;
Beijersbergen, RL ;
Knoll, JHM ;
Meyerson, M ;
Weinberg, RA .
NATURE MEDICINE, 1999, 5 (10) :1164-1170
[20]   Creation of human tumour cells with defined genetic elements [J].
Hahn, WC ;
Counter, CM ;
Lundberg, AS ;
Beijersbergen, RL ;
Brooks, MW ;
Weinberg, RA .
NATURE, 1999, 400 (6743) :464-468